Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections

This publication has 22 references indexed in Scilit:

• High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus Infections
  Archives of internal medicine (1960), 2006
• Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant Strains
  Clinical Infectious Diseases, 2006
• Accessory Gene Regulator Group II Polymorphism in Methicillin-Resistant Staphylococcus aureus Is Predictive of Failure of Vancomycin Therapy
  Clinical Infectious Diseases, 2004
• Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
  Journal of Clinical Microbiology, 2004
• Treatment Outcomes for Serious Infections Caused by Methicillin‐ResistantStaphylococcus aureuswith Reduced Vancomycin Susceptibility
  Clinical Infectious Diseases, 2004
• Comparison of Community- and Health Care–Associated Methicillin-Resistant Staphylococcus aureus Infection
  JAMA, 2003
• National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003
  American Journal of Infection Control, 2003
• Community‐Acquired Methicillin‐ResistantStaphylococcus aureus:A Meta‐Analysis of Prevalence and Risk Factors
  Clinical Infectious Diseases, 2003
• Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides
  Journal of Clinical Microbiology, 2001
• Analysis of Vancomycin Population Susceptibility Profiles, Killing Activity, and Postantibiotic Effect against Vancomycin-Intermediate Staphylococcus aureus
  Antimicrobial Agents and Chemotherapy, 1999